GSK 6-K
GSK plc (GSK)
6-K
2026-07-17
For: 2026-07-17
View Original
Added on
July 17, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 17 July 2026, London UK
GSK provides an
update on CALM-1 and CALM-2 phase III trials for camlipixant in
refractory chronic cough (RCC)
GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and
CALM-2 phase III clinical trials, which assessed the efficacy and
safety of two doses of camlipixant (a P2X3 receptor antagonist) in
adults with refractory chronic cough (RCC).1,2 RCC
is a complex and under-recognised disease with limited treatment
options.3-5
CALM-1 met its primary endpoint with camlipixant 50mg twice daily
showing statistically significant reductions in 24-hour cough
frequency versus placebo at week 12. CALM-2 did not reach
statistical significance in the same primary endpoint with 50mg
twice daily at week 24. Camlipixant 25mg twice daily did not reach
statistical significance in either study. Key secondary endpoints,
including a Chronic Cough Diary (CCD) measure, did not meet target
thresholds in either study. Across both trials, the overall
incidence and severity of treatment-related adverse events were
similar in patients receiving either camlipixant or
placebo.
Based on the aggregate data, the limited efficacy demonstrated is
unlikely to transform patient care. GSK has decided not to progress
further development of camlipixant in RCC. Results from the CALM
phase III programme will be submitted for future
presentation/publication to contribute to the scientific
understanding of RCC.
The phase IIb BALANCE trial (NCT07519395) will continue to evaluate
the efficacy and safety of camlipixant in adults with irritable
bowel syndrome - diarrhoea (IBS-D) and irritable bowel syndrome -
mixed (IBS-M).6
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Sarah Clements
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Sydney Dodson-Nease
|
+1 215 370 4680
|
(Philadelphia PA)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Sam Piper
|
+44 (0) 7824 525779
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2025, and
GSK's Q1 Results for 2026.
This announcement contains inside information. The person
responsible for arranging the release of this announcement on
behalf of GSK is Victoria Whyte, Company
Secretary.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
References
1.
ClinicalTrials.gov. A
52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With
Refractory Chronic Cough (CALM-1). Available at: https://clinicaltrials.gov/study/NCT05599191 Last
accessed July 2026
2.
ClinicalTrials.gov. A 24-Week Study of the Efficacy and Safety of
BLU-5937 in Adults
With Refractory Chronic Cough (CALM-2).
Available at: https://clinicaltrials.gov/study/NCT05600777 Last
accessed July
2026
3. Garceau D, Chauret N.
BLU-5937: a selective P2X3 antagonist with potent anti-tussive
effect and no taste alteration. Pulm Pharmacol
Ther. 2019;56:56-62.
4. Garceau D, et al. BLU-5937: a
highly selective P2X3 homotrimeric receptor antagonist with
improved taste safety profile in healthy
subjects. Am J Respir Crit Care
Med. 2019;199:A7396
(Poster presented at American Thoracic Society [ATS]; 2019; Dallas,
TX, USA)
5. Austin DJ, Zamacona M.
Investigating camlipixant P2X3 selectivity and taste disturbance: a
model-based dose-response meta-analysis. Am J Respir Crit Care
Med. 2025;211(Suppl
1):A1979.
6.
ClinicalTrials.gov. A Study to Investigate Abdominal Symptoms With
Camlipixant Compared With Placebo in Adults With Irritable Bowel
Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed
(IBS-M) (BALANCE). Available at: https://clinicaltrials.gov/study/NCT07519395 Last
accessed July 2026
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
17, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|